Guglielmo Priscilla, Alongi Pierpaolo, Baratto Lucia, Abenavoli Elisabetta, Buschiazzo Ambra, Celesti Greta, Conte Miriam, Filice Rossella, Gorica Joana, Jonghi-Lavarini Lorenzo, Lanzafame Helena, Laudicella Riccardo, Librando Maria, Linguanti Flavia, Mattana Francesco, Miceli Alberto, Olivari Laura, Piscopo Leandra, Romagnolo Cinzia, Santo Giulia, Vento Antonio, Volpe Fabio, Evangelista Laura
Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, 90127 Palermo, Italy.
Life (Basel). 2023 Aug 28;13(9):1821. doi: 10.3390/life13091821.
FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imaging, which have demonstrated several advantages over [F]FDG, especially in the case of low-grade or well-differentiated tumors. We conducted this systematic review to evaluate all the studies where a head-to-head comparison had been performed to explore the potential utility of FAPI tracers in clinical practice. FAPI-based radiopharmaceuticals have shown promising results globally, in particular in detecting peritoneal carcinomatosis, but studies with wider populations are needed to better understand all the advantages of these new radiopharmaceuticals.
基于FAPI的放射性药物是一类新型示踪剂，主要用于PET成像，与[F]FDG相比已显示出若干优势，尤其是在低级别或高分化肿瘤的情况下。我们进行了这项系统评价，以评估所有进行了直接比较的研究，以探索FAPI示踪剂在临床实践中的潜在效用。基于FAPI的放射性药物在全球范围内已显示出有前景的结果，特别是在检测腹膜癌方面，但需要在更广泛的人群中开展研究，以更好地了解这些新型放射性药物的所有优势。
